Werewolf Therapeutics, INC 10-Q quarterly reports

Werewolf Therapeutics, Inc. reported its second quarter 2026 financial results, highlighting a significant revenue stream from an asset sale to Jazz Pharmaceuticals, but also acknowledging substantial doubt about its ability to continue as a going concern.

Werewolf Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a strategic review process, workforce reduction, and financial performance.

Werewolf Therapeutics, an early-stage biopharmaceutical company, reported substantial doubt about its ability to continue as a going concern, with significant cash burn and increased net losses.

Werewolf Therapeutics reported a wider net loss and increased cash burn in Q2 2025 as it advances its oncology pipeline and seeks future funding.

Werewolf Therapeutics reports a net loss for Q1 2025 but maintains a solid cash position expected to fund operations into Q4 2026.

Werewolf Therapeutics reports a net loss of $16.7 million for the third quarter of 2024, with ongoing clinical trials for WTX-124 and WTX-330.

Werewolf Therapeutics, a biopharmaceutical company developing novel cancer immunotherapies, announced progress in its Phase 1/1b clinical trials for WTX-124 and WTX-330, alongside a new $60 million loan agreement.

Werewolf Therapeutics reported a net loss of $16.2 million for the first quarter of 2024, while highlighting progress in clinical trials and manufacturing.